|Articles|May 1, 2002
- Applied Clinical Trials-05-01-2002
Identifying and Documenting Adverse Events at Clinical Study Sites
Improving adverse event reporting can lead to improved safety profiles and, consequently, fewer drugs pulled from the market.
Advertisement
Articles in this issue
over 23 years ago
Letters to the Editorover 23 years ago
Parents for Orphansover 23 years ago
Fraud, Abuse, and Consentover 23 years ago
Brian Koziolover 23 years ago
A Model-Based Method for Improving Protocol QualityNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Challenges of Buying Blind: Why Providing the Clinical Outcome Assessment Measure Prior to License Execution Would Significantly Benefit Clinical Trial Set-Up
2
Moving Beyond Historical Site Data to Real-Time Patient Insight
3
ACT Brief: Trial Competition Slows AI Gains, Rethinking Patient-Level Safety Decisions, and What Separates Real AI Platforms in Clinical Trials
4
ACT Brief: Community Sites Compete on Readiness, COA Licensing Bottlenecks Slow Start-Up, and AI’s Foundations in Pharmacovigilance
5